Answers are grounded in this paper and cite their sources.
Retrospective cohort study reveals no link between antiphospholipid antibodies and long COVID in COVID-19 patients, suggesting confounding factors.
Introduction Long COVID is a public health issue with complex pathophysiology, potentially involving immunoinflammatory and prothrombotic mechanisms. Antiphospholipid antibodies (aPL) have been observed in acute COVID-19 and speculated to contribute to long COVID development. Our goal was to determine if the presence of aPL was associated with the progression towards long COVID. Methods We retrospectively analyzed all adult patients screened for aPL during acute COVID-19 in our institution between April 2020 and April 2022. Only patients with at least one follow-up ≥3 months post-infection were included. Results Among 114 patients (median age 64.0 years, 44.7% female), 19 (16.7%) developed long COVID. Those with long COVID were younger and more frequently admitted to ICU than those who recovered. However, aPL positivity did not differ significantly between patients with and without long COVID (63.2% vs. 66.3%, p = 0.79). Conclusion Our findings suggest no association between aPL and the development of long COVID. Prior associations may reflect confounding factors such as ICU admission.
No takes yet. Share an insight, caveat, or question.
Arcani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: